Data / Form D filings / Ascend Gene & Cell Therapies Ltd.
Ascend Gene & Cell Therapies Ltd.: Form D filing
Ascend Gene & Cell Therapies Ltd., a company in Altrincham, United Kingdom, filed a Form D with the SEC in 2023. The latest, on March 1, 2023, reports $66.6 million sold of a $66.6 million offering to 10 investors.
SpecStream is the live web data engine for teams and agents. It reads every Form D on SEC EDGAR the day it is filed, and this page is that reading. Ask for your own cut (a state, an industry, a size) and new filings arrive in your sheet, CRM, Slack or agent as they land.
Company details from the filing
- Address
- 1 ASHLEY ROAD, 3RD FLOOR, Altrincham, United Kingdom, WA14
- Phone
- 020-814-83794
- Industry
- Other
- Entity type
- Corporation
- Incorporated in
- United Kingdom
- Year incorporated
- 2021
- Revenue range
- Decline to Disclose
- Exemptions claimed
- Rule 506(b)
- SEC identifier (CIK)
- 1967249
Form D filings
| Filed | Type | Offering | Sold | Remaining | Investors | First sale | Filing |
|---|---|---|---|---|---|---|---|
| Mar 1, 2023 | New notice | $66,624,999 | $66,624,999 | 10 | Feb 7, 2023 | sec.gov |
Executive officers and directors named in the filing
| Name | Role | Note in the filing |
|---|---|---|
| Timothy Funnell | Executive Officer, Director | |
| Michael Beecham | Director | |
| Fred Cohen | Director | |
| Eric Shiozaki | Director | |
| Balaji Muralidhar | Director | |
| Andrew Sinclair | Director | |
| Andrew May | Director |
Every Form D from the week of Feb 27, 2023 · All recent Other filings
Read from SEC EDGAR. Amount sold is what Ascend Gene & Cell Therapies Ltd. reported on the day it filed; on an offering that is still open, a later amendment can raise it. Free to reuse with credit to SpecStream under CC BY 4.0.